Sage Journals: Discover world-class research

Abstract

Background:

We report a case of nivolumab-related sarcoidosis-like syndrome that initially presented with erythema nodosum. Sarcoidosis development has been described in single and combination immunotherapy.

Case Presentation:

A 68-year-old white woman with metastatic ocular amelanotic choroid melanoma was treated with nivolumab. The patient developed histologically confirmed erythema nodosum lesions and pulmonary granuloma sarcoidosis. Nivolumab was discontinued and the patient started ipilimumab therapy.

Conclusion:

Sarcoidosis-like syndrome with lymphadenopathy is a rare adverse event that is important to recognize since it can be mistaken for metastatic disease progression. Tissue biopsy of new lesions during immunotherapy is an important step in patient evaluation.

Keywords

erythema nodosum sarcoidosis metastatic melanoma nivolumab immune-related adverse event

Get full access to this article

View all access options for this article.

References

Fisher

Flaherty

Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol. 2015;1(9):1340-1341.

Yin

Totonchy

Leventhal

JS.

Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding. JAAD Case Rep. 2017;3(2):90-92.

Sanlorenzo

Vujic

Daud

et al . Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206-1212.

Braun

Celada

Herazo-Maya

et al . Blockade of the programmed death-1 pathway restores sarcoidosis CD4 T-cell proliferative capacity. Am J Respir Crit Care Med. 2014;190(5):560-571.

Reuss

Kunk

Stowman

et al . Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. J Immunother Cancer. 2016;4(1):94.

Tetzlaff

Jazaeri

Torres-Cabala

et al . Erythema nodosum-like panniculitis mimicking disease recurrence: a novel toxicity from immune checkpoint blockade therapy—report of 2 patients. J Cutan Pathol. 2017;44(12):1080-1086.

Montaudié

Pradelli

Passeron

et al . Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol. 2017;176(4):1060-1063.

Danlos

Pagès

Baroudjian

et al . Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149(5):e133-e136.

Firwana

Ravilla

Raval

et al . Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2017;23(8):620-624.

10.

Suozzi

Stahl

et al . Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep. 2016;2(3):264-268.

11.

Kim

Gao

Shannon

et al . Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Rep. 2016;1:1032.

12.

Vogel

Guislain

Kvistborg

et al . Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 2012;30(2):e7-e10.

13.

Yatim

Mateus

Charles

Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission. Rev Med Interne. 2018;39(2):130-133.

14.

Berthod

Lazor

Letovanec

et al . Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012;30(17):e156-e159.

15.

Wilgenhof

Morlion

Seghers

et al . Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res. 2012;32(4):1355-1359.

16.

Puzanov

Diab

Abdallah

et al . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):1-29.